The clock starts ticking once the vaccine leaves the freezer. Here's what to expect.
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
The arrival of COVID-19 vaccines has raised hope for an end to the pandemic. Hopefully that's true, but there are variables. Here are some factors that could affect the success of the vaccine rollout.
The approval of the first of four COVID-19 vaccines marks the first step in New Zealand's plans for a Pacific-wide immunisation rollout.
Israel is vaccinating its population at an impressive rate and sharing the data with the world. But at what price?
With richer countries having bought up most of the leading western vaccines, others are looking to India, China and Russia for supplies.
We have limited information about the reported deaths of 30 elderly people in Norway who had received the Pfizer COVID vaccine. Here's what we do know.
Rollout of COVID-19 vaccines has begun. But getting the jab doesn't mean abandoning masks, distancing and handwashing. Here's why the current preventive measures must continue post-vaccine.
In our first weekly update on COVID vaccines, we consider how roll-out plans are being tweaked and when it's likely we'll start to see vaccines having an impact.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that's to be expected.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it's better to give one dose to more people and give a second when the supply is better.
With vaccines forthcoming for most Americans, many groups, including expectant mothers, are wondering if the vaccine is safe for them and their babies. A physician-scientist explains.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn't a big problem, but the data isn't in yet.
Experts from across The Conversation assess the work that's helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Here's what we still need to find out before we can know when we'll be able to return to our pre-coronavirus ways.
We still need to know exactly what part of the immune response offers protection – and how strong it needs to be to remain protective.
COVID-19 vaccine testing on children is just getting started, and only in adolescents.
Vaccine hesitancy is not new, but it has a new element: few people can remember the devastating impact of diseases such as smallpox and polio and it is hard to see the lives saved by vaccination.